Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.57 USD | +0.14% | +1.13% | -53.33% |
May. 21 | Top Midday Decliners | MT |
May. 21 | GT Biopharma Prices $3.2 Million Registered Direct Offering of Shares, Concurrent Private Placement of Warrants | MT |
Financials (USD)
Sales 2022 | - | Sales 2023 | - | Capitalization | 10.56M |
---|---|---|---|---|---|
Net income 2022 | -20M | Net income 2023 | -7M | EV / Sales 2022 | - |
Net cash position 2022 | 16.33M | Net cash position 2023 | 13.91M | EV / Sales 2023 | - |
P/E ratio 2022 |
-1.35
x | P/E ratio 2023 |
-1.36
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 89.34% |
1 day | +0.14% | ||
1 week | +1.13% | ||
Current month | -4.80% | ||
1 month | +8.18% | ||
3 months | -21.19% | ||
6 months | -48.71% | ||
Current year | -53.33% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Breen
CEO | Chief Executive Officer | 61 | 21-01-12 |
Manu Ohri
DFI | Director of Finance/CFO | 68 | 22-02-17 |
Jeffrey Miller
PRN | Corporate Officer/Principal | - | 22-12-13 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 78 | 23-04-30 | |
Bruce Wendel
BRD | Director/Board Member | 70 | 20-11-10 |
Rajesh Shrotriya
BRD | Director/Board Member | 79 | 21-01-12 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-04 | 3.52 | -1.26% | 17,080 |
24-06-03 | 3.565 | -4.93% | 77,317 |
24-05-31 | 3.75 | -2.85% | 17,663 |
24-05-30 | 3.86 | +9.35% | 67,975 |
24-05-29 | 3.53 | 0.00% | 86,260 |
Delayed Quote Nasdaq, June 04, 2024 at 03:58 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-53.33% | 7.69M | |
+42.83% | 748B | |
+34.11% | 598B | |
-5.70% | 356B | |
+18.06% | 325B | |
+4.63% | 283B | |
+17.02% | 245B | |
+9.26% | 211B | |
-4.21% | 209B | |
+2.43% | 166B |
- Stock Market
- Equities
- GTBP Stock